Compare IBRX & USA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IBRX | USA |
|---|---|---|
| Founded | 2014 | 1986 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 1.9B |
| IPO Year | N/A | N/A |
| Metric | IBRX | USA |
|---|---|---|
| Price | $2.05 | $6.27 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $9.71 | N/A |
| AVG Volume (30 Days) | ★ 13.6M | 880.5K |
| Earning Date | 11-04-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.66% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $82,555,000.00 | N/A |
| Revenue This Year | $667.18 | N/A |
| Revenue Next Year | $93.03 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1025.95 | N/A |
| 52 Week Low | $1.83 | $5.62 |
| 52 Week High | $4.27 | $7.09 |
| Indicator | IBRX | USA |
|---|---|---|
| Relative Strength Index (RSI) | 45.08 | 54.39 |
| Support Level | $1.95 | $6.27 |
| Resistance Level | $2.29 | $6.34 |
| Average True Range (ATR) | 0.12 | 0.07 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 19.09 | 64.58 |
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
Liberty All Star Equity Fund is a multi-managed fund. Its objective is to provide a high level of current income and long-term capital appreciation through investing principally in a diversified portfolio of equity securities. The fund invests in various sectors, including financials, information technology, healthcare, consumer discretionary, consumer staples, industrials, energy, materials, real estate, utilities, telecommunication, and other services.